Bank of Montreal Can Increases Position in Verona Pharma PLC American Depositary Share $VRNA

Bank of Montreal Can raised its position in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 882.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,141 shares of the company’s stock after buying an additional 76,472 shares during the period. Bank of Montreal Can owned about 0.10% of Verona Pharma PLC American Depositary Share worth $8,053,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of VRNA. Frazier Life Sciences Management L.P. boosted its holdings in Verona Pharma PLC American Depositary Share by 2.2% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 3,457,850 shares of the company’s stock valued at $219,539,000 after acquiring an additional 73,900 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Verona Pharma PLC American Depositary Share by 1.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,866,280 shares of the company’s stock worth $118,491,000 after purchasing an additional 32,748 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Verona Pharma PLC American Depositary Share by 381.9% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,631,000 shares of the company’s stock worth $103,552,000 after purchasing an additional 1,292,575 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Verona Pharma PLC American Depositary Share by 274.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company’s stock valued at $66,119,000 after purchasing an additional 763,353 shares during the period. Finally, Duquesne Family Office LLC grew its holdings in shares of Verona Pharma PLC American Depositary Share by 12.9% in the first quarter. Duquesne Family Office LLC now owns 1,002,080 shares of the company’s stock valued at $63,622,000 after purchasing an additional 114,500 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Verona Pharma PLC American Depositary Share Price Performance

VRNA stock opened at $106.91 on Monday. The business has a 50 day moving average price of $106.65 and a 200 day moving average price of $96.49. The stock has a market cap of $9.21 billion, a price-to-earnings ratio of -107.99 and a beta of 0.05. Verona Pharma PLC American Depositary Share has a fifty-two week low of $31.09 and a fifty-two week high of $106.93. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. HC Wainwright restated a “neutral” rating and set a $107.00 price target (up previously from $90.00) on shares of Verona Pharma PLC American Depositary Share in a report on Monday, July 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Verona Pharma PLC American Depositary Share in a research report on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 target price on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Verona Pharma PLC American Depositary Share to a “hold” rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $109.00.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.